Coincidentally, PVmed also launched the very first CODVID-19 AI-assisted diagnosis system to help the frontline clinicians to fight against the spread of this novel virus in China early this year. It is PVmed's goal to provide auxiliary diagnosis and treatment of diseases and provide complete solutions in radiation oncology and radiology.

The assisted diagnostic tool for this pandemic is only a small apart of its solutions. PVmed has developed several products, including intelligent targets contouring on radiotherapy for nasopharyngeal cancer (NPC), which is the first commercial product in the world, medical image post-processing system, which was approved by NMPA for Class II medical devices, pulmonary nodules diagnostic system, ribs suppression system, etc. These products have been in the clinical trial application or marketing and sales process. In particular, the intelligent radiotherapy contouring system has been deployed in multiple leading hospitals in China such as Sun Yat-Sen University Cancer Center, Sichuan Cancer Hospital, National Cancer Center Singapore (NCCS), and other leading hospitals where the OARs, GTV, and CTV delineation are needed and appreciated by the physicians.


"It is a growing consensus in the industry that AI has played a major role in clinical applications," said Prof. Yao Lu, PVmed's co-founder and Chairman. "We are facing the challenges of speeding up the technology innovation to meet increasing clinical needs at scale. To meet this challenge, PVmed is excited to join forces and collaborate with RADLogics to explore safer, more intelligent, and efficient AI medical imaging solutions that digitalize the workload of the radiology and radiation oncology departments in multiple international markets. By doing so, democratizing the access to quality AI assisted medical care and contributing to the new intelligent healthcare ecosystem of the future."


Take it to the next level

It was in 2018 that PVmed and RADLogics started the conversation in terms of sharing technologies and products both companies already have. With two years of discussion and ideas exchanges, PVmed and RADLogics have built a strong mutual trust and come together to advance the solutions and market development in AI medical imaging.

"After years of development, verification, and improvement of medical imaging products, it starts to serve clinicians and patients thanks to joint efforts of researchers, regulatory agencies, and commercial companies in this area," said Sean Shen, PVmed's CEO. "The medical imaging AI has moved into a stage of fast-growing not only in China but also in other global markets. Due to the fact that medical imaging device has a long development cycle and its own regionality, medical enterprise needs to have firm relationships with partners and ecosystem. Therefore, PVmed would like to achieve breakthroughs and win-win situations in several fields with innovative companies like RADLogics having cutting-edge technologies and accumulated advantages."

Artificial Intelligence Homepage